Tourmaline Bio Inc. (TRML NASDAQ) stock market data APIs
$47.6579
0(0%)
as of October 30, 2025
Try our APIs with
free plan!
Tourmaline Bio Inc. Financial Data Overview
Price chart is built with
Anychart
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Tourmaline Bio, Inc. operates as a subsidiary of Novartis AG.
Prev. Close
47.6579
Open
47.6579
High
47.6579
Low
47.6579
52 wk Range
11.56-48.27
Market Cap
1 233 M
Shares Outstanding
25 692 K
EPS
-1.79
Beta
1.581
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tourmaline Bio Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tourmaline Bio Inc. data using free add-ons & libraries
Get Tourmaline Bio Inc. Fundamental Data
Tourmaline Bio Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -102 406 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -0.91
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tourmaline Bio Inc. News
New
Novartis Profit Rises on Cancer Drug Momentum
This article first appeared on GuruFocus. Novartis (NYSE:NVS) had a solid quarter, with strong sales of its cancer drugs giving profits a nice lift. The Swiss pharma giant said core operating profit ...
Novartis completes acquisition of Tourmaline Bio
Novartis Pharma AG Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisi...
Novartis Q3 profit swells as oncology drugs drive growth
[Novartis] TBE/iStock Editorial via Getty Images Novartis (NYSE:NVS [https://seekingalpha.com/symbol/NVS]) reported a solid profit increase last quarter, driven by strong demand for its new cancer dr...
Novartis announces expiration of Tourmaline Bio tender offer
Novartis Pharma AG Basel, October 28 2025 - Novartis today announced that its previously announced tender offer (the “offer”) by Torino Merger Sub Inc., a Delaware corporation and an indirect who...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
